16 Nov Inside Kine’s Approach to Modern Cannabinoid Wellness Products
Cannabis/CBD Notice: Cannabis products are not FDA monitored or approved. Discuss your use of medicinal cannabis or CBD products with your healthcare provider before use. Dosing is variable and products may interfere with other medications, stimulants and alcohol. Do not use cannabis or CBD products if you are pregnant, nursing, or may become pregnant. Do not use cannabis products when driving or operating difficult or dangerous machinery. Keep out of reach of children. Children and pets should not be exposed to cannabis or CBD products.
Editorial Notice: This article discusses products from a specific hemp cannabinoid brand. It is not specific medical advice, and products and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.
Cannabinoid wellness products are becoming increasingly specialized, with differences in formulation, delivery methods and ingredient selection shaping the consumer experience. Kine approaches this evolving category by combining hemp-derived cannabinoid isolates with thoughtfully selected ingredients and straightforward product formats designed for everyday use.
Through its Tinctures, Drops/Lozenges and Balm, Kine emphasizes the relationship between product design and potential wellness applications. Its sugar-free formulations, natural flavors and focus on individual cannabinoids reflect an approach that considers not only what goes into a product, but also how it is administered and incorporated into a routine.
Dr. Basavana Goudra[/caption]
Dr. Goudra: Cannabis use is increasingly common, and anesthesia providers are consequently encountering more patients who use cannabis before procedural sedation and anesthesia. This has become an important perioperative issue because cannabinoids can have complex effects on the central and peripheral nervous systems, and their pharmacologic effects vary with the dose, potency, frequency, and route of administration.
Dr. Edward Liu[/caption]
MedicalResearch.com Interview with:
Edward Liu, MD
Geisinger College of Health Sciences
Scranton, PA 18509
Medicalresearch.com: What is the background for this study?
Response: Prescription drugs have high levels of uniformity that plant-based products cannot achieve. Given the liberalization of state-laws regarding medical marijuana1 over the past three-decades and increasing evidence of evidence of cannabis for conditions like chronic pain,2 we were interested in the use of the prescription formulation of delta(Δ)9-tetrahydrocannabinol (THC). A prior pharmacoepidemiology report found that prescription THC (dronabinol) to Medicaid patients decreased from 2016 to 2020. There were also pronounced state-level disparities in prescribing with a 130-fold difference when correcting for population between the highest and lowest states.
There was no research on this topic among Medicare patients. To address this gap, we obtained prescription numbers nationally and at a state level from 2014 to 2019 for Medicare Part D patients.
Source: IMAGE[/caption]
Dr. Kruger[/caption]
MedicalResearch.com: What is the background for this study?
[caption id="attachment_72137" align="alignleft" width="100"]
Dr. Felicione[/caption]
Response: Alcohol consumption, especially heavy alcohol consumption, is associated with many health risks and nearly 200 different health conditions and diseases. Reducing alcohol consumption reduces the risks and harms from alcohol. Previous research has demonstrated that people have reduced their alcohol consumption when they have access to cannabis. Cannabis beverages have emerged in States where cannabis is legal for adult or medical use.